Brown P - Search Results

1

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D, Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J, Karp JE, Small D. Levis M, et al. Among authors: brown p. Blood. 2006 Nov 15;108(10):3477-83. doi: 10.1182/blood-2006-04-015743. Epub 2006 Jul 20. Blood. 2006. PMID: 16857987 Free PMC article.

2

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. Zheng R, et al. Among authors: brown p. Blood. 2004 Jan 1;103(1):267-74. doi: 10.1182/blood-2003-06-1969. Epub 2003 Sep 11. Blood. 2004. PMID: 12969963 Free article.

3

FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer.

Brown P, Small D. Brown P, et al. Eur J Cancer. 2004 Mar;40(5):707-21, discussion 722-4. doi: 10.1016/j.ejca.2003.08.030. Eur J Cancer. 2004. PMID: 15010072 Review.

4

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.

Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D. Brown P, et al. Blood. 2004 Sep 15;104(6):1841-9. doi: 10.1182/blood-2004-03-1034. Epub 2004 May 27. Blood. 2004. PMID: 15166029 Free article.

5

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.

Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. Brown P, et al. Blood. 2005 Jan 15;105(2):812-20. doi: 10.1182/blood-2004-06-2498. Epub 2004 Sep 16. Blood. 2005. PMID: 15374878 Free article.

6

FLT3/ITD mutation signaling includes suppression of SHP-1.

Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D. Chen P, et al. Among authors: brown p. J Biol Chem. 2005 Feb 18;280(7):5361-9. doi: 10.1074/jbc.M411974200. Epub 2004 Dec 1. J Biol Chem. 2005. PMID: 15574429 Free article.

7

IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.

Piloto O, Nguyen B, Huso D, Kim KT, Li Y, Witte L, Hicklin DJ, Brown P, Small D. Piloto O, et al. Among authors: brown p. Cancer Res. 2006 May 1;66(9):4843-51. doi: 10.1158/0008-5472.CAN-06-0018. Cancer Res. 2006. PMID: 16651440

8

Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.

Brown P, Levis M, McIntyre E, Griesemer M, Small D. Brown P, et al. Leukemia. 2006 Aug;20(8):1368-76. doi: 10.1038/sj.leu.2404277. Epub 2006 Jun 8. Leukemia. 2006. PMID: 16761017

9

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. Piloto O, et al. Among authors: brown p. Blood. 2007 Feb 15;109(4):1643-52. doi: 10.1182/blood-2006-05-023804. Epub 2006 Oct 17. Blood. 2007. PMID: 17047150 Free PMC article.

10

The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. Brown P, et al. Blood. 2007 Aug 1;110(3):979-85. doi: 10.1182/blood-2007-02-076604. Epub 2007 Apr 17. Blood. 2007. PMID: 17440048 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,911 results

Search Page